We follow what a supply decision changes

American Peptide Supply is for anyone who has read that a shortage ended and wondered what happens next. Maybe you’re trying to understand your own care. Maybe you’re helping someone else untangle an announcement.

Our name refers to the U.S. medicine-supply picture. We don’t sell medicines or arrange appointments. We explain why a date on the national shortage list can change the conversation about care.

We follow a simple question: what changed, and what does it mean for the person trying to get through the week? The national answer matters. So does the part that still needs sorting out closer to home.

A headline can sound final while leaving you with several practical questions. Why did compounding have more room during the shortage? Why did the rules change afterward? Who can explain what happens with a personal plan?

Our three chapters follow those questions: the shortage timeline, the two compounding frameworks known as 503A and 503B, and keeping care going. You can read the chapter that matches your question without working through the whole site first.

If you’re helping someone else, you may have the same questions they do. The dates can give you a shared starting point. A personal decision still needs someone who can assess that person’s care.

This guide was updated on 27 October 2026. Each event keeps its own date, including the April 2026 policy update. That way, a later visit to this page won’t make an earlier announcement look new.

For a national supply question today, there’s the FDA shortage database. For the difference between approved and compounded medicines, there’s FDA’s compounding explanation. Our references page brings the sources together.

These pages give general information rather than medical or legal advice. A licensed U.S. clinician who can prescribe is the route for a personal treatment decision. We hope the background makes that discussion a little less bewildering.